** Drug developer Neumora Therapeutics' shares fall 82% to $1.95
** NMRA says its experimental depression drug, navacaprant, did not meet the main goal in a late-stage trial
** The drug did not reduce symptoms of depression as measured on a disease severity scale that tracks sadness, reduced sleep and pessimistic thoughts
** NMRA says the drug also did not show statistically significant improvement on a key secondary goal
** Co says its cash balance of $342 mln at the end of the Q3 will fund operations into mid-2026
** NMRA declined ~38% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.